INT278829

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.40
First Reported 2009
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 1.51
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (PVR) extracellular region (PVR) nucleolus (PVR)
plasma membrane (PVR) nucleus (PVR) cytoplasm (PVR)
Anatomy Link Frequency
pulmonary artery 6
PVR (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 45 5.00 Very Low Very Low Very Low
headache 9 5.00 Very Low Very Low Very Low
Calcium channel 9 5.00 Very Low Very Low Very Low
methotrexate 6 5.00 Very Low Very Low Very Low
fibrosis 6 5.00 Very Low Very Low Very Low
Angina 6 5.00 Very Low Very Low Very Low
tolerance 6 5.00 Very Low Very Low Very Low
nud 6 5.00 Very Low Very Low Very Low
cva 6 5.00 Very Low Very Low Very Low
anesthesia 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 294 95.12 Very High Very High Very High
Overactive Bladder 14 79.60 Quite High
Incontinence 29 77.12 Quite High
Systemic Sclerosis 12 53.20 Quite High
Cv General 4 Under Development 30 19.80 Low Low
Death 9 15.48 Low Low
Disease 45 5.00 Very Low Very Low Very Low
Dyspnea 27 5.00 Very Low Very Low Very Low
Increased Venous Pressure Under Development 18 5.00 Very Low Very Low Very Low
Anaemia 15 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
A dose-dependent increase in PVR >100 mL was apparent in men and patients aged >70 years but not in women or patients aged ?
Positive_regulation (increase) of Gene_expression (>100) of PVR
1) Confidence 0.40 Published 2010 Journal BMC Urol Section Body Doc Link PMC2939595 Disease Relevance 0.28 Pain Relevance 0
Eight patients on stable doses of epoprostenol (average 100 ng/kg/min) had continuous hemodynamic monitoring for 2 days during initiation with 62.5 mg bosentan twice daily.35 Even while reducing epoprostenol to maintain SvO2 at baseline value, systolic pulmonary artery pressure and PVR fell; these changes were maintained in six of the patients at 1 year.35
Positive_regulation (during) of Gene_expression (pressure) of PVR in pulmonary artery
2) Confidence 0.23 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2725793 Disease Relevance 0.41 Pain Relevance 0
Eight patients on stable doses of epoprostenol (average 100 ng/kg/min) had continuous hemodynamic monitoring for 2 days during initiation with 62.5 mg bosentan twice daily.35 Even while reducing epoprostenol to maintain SvO2 at baseline value, systolic pulmonary artery pressure and PVR fell; these changes were maintained in six of the patients at 1 year.35
Positive_regulation (during) of Gene_expression (fell) of PVR in pulmonary artery
3) Confidence 0.23 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2725793 Disease Relevance 0.41 Pain Relevance 0
Eight patients on stable doses of epoprostenol (average 100 ng/kg/min) had continuous hemodynamic monitoring for 2 days during initiation with 62.5 mg bosentan twice daily.35 Even while reducing epoprostenol to maintain SvO2 at baseline value, systolic pulmonary artery pressure and PVR fell; these changes were maintained in six of the patients at 1 year.35
Positive_regulation (reducing) of Gene_expression (fell) of PVR in pulmonary artery
4) Confidence 0.23 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2725793 Disease Relevance 0.41 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox